Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Liquidia Corp CFO and COO Michael Kaseta reported option exercises and share sales in April 2026. He exercised incentive stock options to acquire a total of 89,971 shares of common stock at an exercise price of $2.79 per share, from options that were fully vested as of November 30, 2024.
Kaseta then sold an aggregate 142,390 shares of common stock in open-market transactions on April 14–15, 2026 at prices including $40.00 and a volume‑weighted average price of $40.1409, within a range of $40.00 to $40.39. These sales were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the transactions, he directly holds 353,356 shares of common stock, plus additional unvested RSUs and ESPP shares noted in the footnotes.
Serendipity BioPharma LLC and related parties reported multiple resale transactions of restricted common stock of LQDA. The excerpt lists sales including 04/16/2026 entries for 25,000 shares (proceeds $1,003,000.00) and earlier 10b5-1 sales on 04/15/2026 (25,000 shares, $1,003,522.50), 04/14/2026 (3,300 shares, $132,000.00), and other dated entries. The records identify Roger Jeffs as a reporting party for a 04/13/2026 sale of 32,744 shares (proceeds $1,256,387.28).
Serendipity Biopharma filed a Form 144 disclosing recent resale activity under 10b5-1 plans. The excerpt lists four sales: 3,300 shares on 04/14/2026 for $132,000; 32,744 shares on 04/13/2026 for $1,256,387.28; 21,433 shares on 04/10/2026 for $859,876.96; and 25,000 shares on 04/09/2026 for $1,002,887.50.
Michael Kaseta filed a Form 144 reporting proposed sales of Common Stock on 04/15/2026. The filing lists 86,971 shares from an Exercise of Stock Options, 9,044 shares from an Employee Stock Purchase Plan, and 43,375 shares from Restricted Stock Units. The form also summarizes recent 10b5-1 sales, including 133,789 shares on 04/09/2026, 23,821 shares on 04/10/2026, 18,958 shares on 04/13/2026, and 3,000 shares on 04/14/2026, with individual proceeds shown in the filing.
Liquidia Corp’s Chief Commercial Officer Scott Moomaw reported multiple equity transactions involving company stock. On April 10, 2026, he exercised performance stock units, converting a total of 7,465 PSUs into shares of common stock at an exercise price of $0.00 per share.
On April 13, 2026, he then sold 8,861 shares at $38.37 and 1,686 shares at $38.20 in open-market transactions. Footnotes state these shares were sold to cover taxes tied to the settlement of RSUs and PSUs granted in 2023, 2024 and 2025, and that the transactions were executed under Rule 10b5-1 trading plans.
After these transactions, Moomaw directly holds 184,558 shares of common stock, along with substantial unvested RSU and PSU awards referenced in the footnotes, indicating he retains a significant ongoing equity stake in Liquidia.
Liquidia Corp Chief Business Officer Jason Adair reported an open-market sale of 7,301 shares of common stock at $38.37 per share on April 13, 2026. Following this sale, he directly holds 215,426 common shares.
On April 10, 2026, Adair also exercised and settled equity awards, with 3,906 restricted stock units and a total of 6,342 performance stock units converting into the same number of common shares at a $0.00 exercise price. A footnote states the sale was made under a Rule 10b5-1 trading plan and that the shares sold were used to cover taxes tied to RSU and PSU settlements granted in 2023, 2024, and 2025, indicating a largely routine, compensation-related transaction.
Liquidia Corp Chief Accounting Officer Dana Boyle reported routine equity compensation activity and a small open-market sale. On April 10, 2026, Boyle exercised 3,179 Performance Stock Units, converting them into the same number of shares of common stock at a conversion price of $0.00 per share.
On April 13, 2026, Boyle sold 5,101 shares of Liquidia common stock at an average price of $38.37 per share under a Rule 10b5-1 trading plan. According to the filing, these shares were sold to cover taxes associated with the settlement of previously granted RSUs and PSUs. After these transactions, Boyle directly holds 176,918 shares of common stock, along with multiple tranches of unvested RSUs and PSUs that continue to vest over time.
Liquidia Corp CFO and COO Michael Kaseta reported multiple equity transactions in company stock. On April 10, 2026, he exercised 23,821 stock options at $2.79 per share and converted 5,828 and 7,050 Performance Stock Units into common shares on a one-for-one basis. He then sold 23,821 common shares in the open market at a volume weighted average price of $40.1431, pursuant to a Rule 10b5-1 trading plan.
On April 13, 2026, Kaseta sold an additional 18,958 common shares at $38.37 per share, with footnotes stating these shares were sold to cover taxes tied to RSU and PSU settlements and effected under a Rule 10b5-1 plan. After these transactions, he directly holds 405,775 common shares, along with substantial unvested RSUs and PSUs and 11,694 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corp Chief Human Resource Officer Sarah Krepp reported a combination of equity award activity and a small share sale. She exercised 3,179 performance stock units, which converted to the same number of common shares at a $0.00 exercise price, reflecting previously granted compensation vesting. On a separate date, she sold 4,557 common shares in an open-market transaction at $38.37 per share under a pre-arranged Rule 10b5-1 plan, with the filing noting the sale was to cover taxes from RSU and PSU settlements. After these transactions, she directly holds 147,019 common shares and continues to have sizable unvested RSU and PSU awards scheduled to vest over several years.
Liquidia Corp Chief Medical Officer Rajeev Saggar reported multiple equity transactions. He exercised 8,017 performance stock units that converted into the same number of shares of common stock at an exercise price of $0.00 per share. On a later date, he sold 9,220 shares of common stock in an open-market transaction at $38.37 per share, pursuant to a pre-arranged Rule 10b5-1 plan. According to the footnotes, these shares were sold to cover taxes associated with the settlement of previously granted RSUs and PSUs. After these transactions, he directly owned 173,270 shares of common stock, alongside various unvested RSUs and PSUs granted in prior years.